Favipiravir and ribavirin treatment of epidemiologically linked cases of lassa fever

Clinical Infectious Diseases

Volumn 65, Issue 5, 2017, Pages 855-859

  Raabe, Vanessa N ^a   Kann, Gerrit ^b   Ribner, Bruce S ^a   Andres, Andres Morales ^c   Varkey, Jay B ^a   Mehta, Aneesh K ^a   Lyon, G Marshall ^a   Vanairsdale, Sharon ^d   Faber, Kelly ^e   Becker, Stephan ^f   Eickmann, Markus ^f   Strecker, Thomas ^f   Brown, Shelley ^g   Patel, Ketan ^g   De Leuw, Philipp ^b   Schuettfort, Gundolf ^b   Stephan, Christoph ^b   Rabenau, Holger ^b   Klena, John D ^g   Rollin, Pierre E ^g   McElroy, Anita ^g   Ströher, Ute ^g   Nichol, Stuart ^g   Kraft, Colleen S ^a,h   Wolf, Timo ^b   more..

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c Samaritan's Purse   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Hospital of Hope   (United States)

^f PHILIPPS UNIVERSITY MARBURG   (Germany)

^g CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^h EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

Favipiravir; Lassa; Ribavirin; Togo

Indexed keywords

ARTEMETHER PLUS BENFLUMETOL; FAVIPIRAVIR; RIBAVIRIN; AMIDE; ANTIVIRUS AGENT; PYRAZINE DERIVATIVE; VIRUS RNA;

ADULT; ARTICLE; ATRIAL FIBRILLATION; BLOOD SMEAR; CADAVER; CASE REPORT; CLINICAL ARTICLE; DIARRHEA; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; HEADACHE; HUMAN; HYPERTRANSAMINASEMIA; LASSA FEVER; LASSA VIRUS; LOADING DRUG DOSE; MALAISE; MALARIA; MALE; NAUSEA; PHARYNGITIS; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEXUAL TRANSMISSION; SINUS RHYTHM; SORE THROAT; STREPTOCOCCUS GROUP A; THROMBOCYTOPENIA; GENETICS; PATHOPHYSIOLOGY; POLYMERASE CHAIN REACTION; TOGO; VIROLOGY;

ADULT; AMIDES; ANTIVIRAL AGENTS; HUMANS; LASSA FEVER; LASSA VIRUS; MALE; POLYMERASE CHAIN REACTION; PYRAZINES; RIBAVIRIN; RNA, VIRAL; TOGO;

EID: 85030779761     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cix406     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. Lassa fever. Available at: https:// www.cdc.gov/vhf/lassa/. Accessed 18 March 2017.
2. Haas WH, Breuer T, Pfaff G, et al. Imported Lassa fever in Germany: surveillance and management of contact persons. Clin Infect Dis 2003; 36:1254-8.
3. Lo Iacono G, Cunningham AA, Fichet-Calvet E, et al. Using modelling to disentangle the relative contributions of zoonotic and anthroponotic transmission: the case of Lassa fever. PLoS Negl Trop Dis 2015; 9:e3398.
4. McCormick JB, King IJ, Webb PA, et al. Lassa fever. Effective therapy with ribavirin. N Engl J Med 1986; 314:20-6.
5. Safronetz D, Rosenke K, Westover JB, et al. The broad-spectrum antiviral favipiravir protects guinea pigs from lethal Lassa virus infection post-disease onset. Sci Rep 2015; 5:14775.
6. Oestereich L, Rieger T, Lüdtke A, et al. Efficacy of favipiravir alone and in combination with ribavirin in a lethal, immunocompetent mouse model of Lassa fever. J Infect Dis 2016; 213:934-8.
7. World Health Organization. Communicable diseases toolkit Sierra Leone. Available at: http://apps.who.int/iris/bitstream/10665/68741/1/WHO-CDS-2004.25-%28Profile%29.pdf. Accessed 14 June 2016.
8. Olschläger S, Lelke M, Emmerich P, et al. Improved detection of Lassa virus by reverse transcription-PCR targeting the 5' region of S RNA. J Clin Microbiol 2010; 48:2009-13.
9. Vieth S, Drosten C, Lenz O, et al. RT-PCR assay for detection of Lassa virus and related Old World arenaviruses targeting the L gene. Trans R Soc Trop Med Hyg 2007; 101:1253-64.
10. Sissoko D, Laouenan C, Folkesson E, et al; JIKI Study Group. Experimental treatment with favipiravir for Ebola virus disease (the JIKI trial): a historically controlled, single-arm proof-of-concept trial in Guinea. PLoS Med 2016; 13:e1001967.
11. Schmitz H, Köhler B, Laue T, et al. Monitoring of clinical and laboratory data in two cases of imported Lassa fever. Microbes Infect 2002; 4:43-50.
12. Varkey JB, Shantha JG, Crozier I, et al. Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med 2015; 372:2423-7.
13. Uyeki TM, Erickson BR, Brown S, et al. Ebola virus persistence in semen of male survivors. Clin Infect Dis 2016; 62:1552-5.
14. Sow MS, Etard JF, Baize S, et al; Postebogui Study Group. New evidence of long-lasting persistence of Ebola virus genetic material in semen of survivors. J Infect Dis 2016; 214:1475-6.
15. Schildknecht A, Welti S, Geuking MB, Hangartner L, van den Broek M. Absence of CTL responses to early viral antigens facilitates viral persistence. J Immunol 2008; 180:3113-21.